Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377310 | 0.87 | SLC1A3 (0.41) | PRCPACLYCASRSLC1A3SLC1A2 | |
| SCHEMBL12377303 | 0.87 | PRCP (0.47) | PRCPMALT1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377301 | 0.84 | PPARG (0.39) | PDE2ATTKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377297 | 0.80 | HSD17B10 (0.43) | — | |
| SCHEMBL12377283 | 0.77 | MAPT (0.42) | — | |
| SCHEMBL12413913 | 0.77 | SLC1A3 (0.39) | ACLYCASRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377308 | 0.75 | SPHK1 (0.36) | — | |
| SCHEMBL12377291 | 0.72 | MET (0.43) | — | |
| SCHEMBL12377309 | 0.71 | PRCP (0.43) | PRCPSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377294 | 0.71 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | PRCP 1394/4885PDE2A 2984/4885TTK 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.